The global hemophilia treatment market is on a strong growth trajectory, with projections indicating a rise from USD 12.1 billion in 2024 to a remarkable USD 18.7 billion by 2034. This growth, driven ...
Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...
The Cybersecurity and Global Policy Program is co-led by Isak Nti Asare, assistant dean of undergraduate education and ...
Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...
The Global X Cybersecurity ETF was started in 2019 and has holdings in cybersecurity stocks from the U.S. and abroad. Roughly ...
Foreign Minister Melanie Joly said Canada needs more intelligence sharing and cooperation on defense from countries “we are ...
As World Tuberculosis Day on March 24, 2025, approaches, global health authorities yet again find themselves at a crucial juncture in efforts to tackle the continuing global emergency of tuberculosis.
Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s MHLW for use in conjunction with VRd to treat newly diagnosed ...
Food fuels our bodies and connects us to culture, livelihoods, and the environment. However, today’s food systems contribute ...
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ...
BNY Mellon Global Equity Income Fund underperformed its benchmark index, the FTSE World Index, during the fourth quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback